BIO-RAD LABORATORIES -CL B
BIO.BNYSE🏆 #871 by market capEarnings Oct 22 · PostUS Equity
$298.50▲ $9.58 (+3.21%)
Market closed · at closeTrack BIO.B
Get earnings, price moves & breaking news on Telegram
24h▲ 3.2%
7d▲ 0.0%
14d▲ 0.0%
30d▲ 0.0%
ytd—
1y—
🏦Market Cap
$7.99B
Small Cap
📈Revenue Growth (YoY)
+1.4%
Slowing
📊Gross Margin
51.9%
Healthy
💵FCF Margin
13.6%
Healthy
⚖️P/S Ratio
3.9x
Fair
Otter Score
60
Fair
Trading Snapshot
- Day Range
- $295.81 – $304.27
- 52-Week Range
- $236.73 – $396.23
- Volume
- $3.09B
- Avg Volume
- $3.33B
- Shares Outstanding
- 26.8M
- Next Earnings
- Dec 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.60B
- Last Q Revenue
- $715M
- P/E Ratio
- 45.7
- P/S Ratio
- 3.9x
- EPS (TTM)
- $8.25
- Dividend Yield
- —
Why Investors Own BIO.B
- ✓High-growth profile — revenue up +49.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BIO-RAD LABORATORIES -CL B
BIO.BFinancial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$2.60B▲ +44.8% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
44.7%▲ +0.0% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$743M▲ +44.8% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$174M▲ +44.8% YoY
StockOtter · stockotter.spaceAbout BIO-RAD LABORATORIES -CL B
A company profile for BIO-RAD LABORATORIES -CL B isn’t available yet — check back soon.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy1
Buy4
Hold4
Sell1
Strong Sell0
Ratings as of Sep 2026
Latest News & Updates
🚀
Reuters·2h ago
BIO-RAD LABORATORIES -CL B tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift BIO.B price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
BIO-RAD LABORATORIES -CL B announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.